nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CHRM3—ureter—urinary bladder cancer	0.0559	0.267	CbGeAlD
Cevimeline—CHRM3—muscle of abdomen—urinary bladder cancer	0.0403	0.192	CbGeAlD
Cevimeline—FMO1—prostate gland—urinary bladder cancer	0.0159	0.0757	CbGeAlD
Cevimeline—FMO1—renal system—urinary bladder cancer	0.0108	0.0516	CbGeAlD
Cevimeline—FMO1—urethra—urinary bladder cancer	0.0106	0.0507	CbGeAlD
Cevimeline—CYP3A4—urine—urinary bladder cancer	0.00998	0.0476	CbGeAlD
Cevimeline—CYP2D6—urine—urinary bladder cancer	0.00982	0.0469	CbGeAlD
Cevimeline—FMO1—vagina—urinary bladder cancer	0.00784	0.0374	CbGeAlD
Cevimeline—CHRM1—prostate gland—urinary bladder cancer	0.00729	0.0348	CbGeAlD
Cevimeline—CHRM3—prostate gland—urinary bladder cancer	0.00652	0.0311	CbGeAlD
Cevimeline—FMO1—lymph node—urinary bladder cancer	0.00507	0.0242	CbGeAlD
Cevimeline—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00462	0.022	CbGeAlD
Cevimeline—CHRM3—renal system—urinary bladder cancer	0.00445	0.0212	CbGeAlD
Cevimeline—CHRM3—urethra—urinary bladder cancer	0.00437	0.0208	CbGeAlD
Cevimeline—CHRM1—female reproductive system—urinary bladder cancer	0.00398	0.019	CbGeAlD
Cevimeline—CHRM3—female reproductive system—urinary bladder cancer	0.00356	0.017	CbGeAlD
Cevimeline—CYP3A4—renal system—urinary bladder cancer	0.00244	0.0116	CbGeAlD
Cevimeline—CYP2D6—renal system—urinary bladder cancer	0.0024	0.0115	CbGeAlD
Cevimeline—CYP3A4—female reproductive system—urinary bladder cancer	0.00196	0.00933	CbGeAlD
Cevimeline—CYP2D6—female reproductive system—urinary bladder cancer	0.00193	0.00918	CbGeAlD
Cevimeline—FMO1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00127	0.00818	CbGpPWpGaD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00125	0.00801	CbGpPWpGaD
Cevimeline—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00123	0.00791	CbGpPWpGaD
Cevimeline—FMO1—Biological oxidations—GSTM1—urinary bladder cancer	0.00119	0.00762	CbGpPWpGaD
Cevimeline—FMO1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00117	0.00752	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00101	0.0065	CbGpPWpGaD
Cevimeline—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000916	0.00589	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000821	0.00528	CbGpPWpGaD
Cevimeline—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000815	0.00524	CbGpPWpGaD
Cevimeline—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000804	0.00517	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GSTZ1—urinary bladder cancer	0.000791	0.00508	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GSTO2—urinary bladder cancer	0.000749	0.00482	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—NAT1—urinary bladder cancer	0.000749	0.00482	CbGpPWpGaD
Cevimeline—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000702	0.00451	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000688	0.00442	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—UGT2B7—urinary bladder cancer	0.000685	0.00441	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000678	0.00436	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000661	0.00425	CbGpPWpGaD
Cevimeline—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000658	0.00423	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000652	0.00419	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000652	0.00419	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000643	0.00413	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CYP4B1—urinary bladder cancer	0.000617	0.00397	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000596	0.00383	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000588	0.00378	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—SLC19A1—urinary bladder cancer	0.000583	0.00375	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PRSS3—urinary bladder cancer	0.000568	0.00365	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000537	0.00345	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000529	0.0034	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—TYMP—urinary bladder cancer	0.000454	0.00292	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00045	0.00289	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000443	0.00285	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000426	0.00274	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000426	0.00274	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00042	0.0027	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—NAT2—urinary bladder cancer	0.000411	0.00264	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00039	0.00251	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000384	0.00247	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000357	0.0023	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—RRM2—urinary bladder cancer	0.000354	0.00228	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000352	0.00226	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000351	0.00226	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000346	0.00223	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—HPGDS—urinary bladder cancer	0.000328	0.00211	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ENO2—urinary bladder cancer	0.000328	0.00211	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GSTT1—urinary bladder cancer	0.000318	0.00205	CbGpPWpGaD
Cevimeline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000302	0.00194	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000286	0.00184	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000277	0.00178	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—urinary bladder cancer	0.000268	0.00173	CbGpPWpGaD
Cevimeline—Weight decreased—Doxorubicin—urinary bladder cancer	0.000268	0.000422	CcSEcCtD
Cevimeline—Sinusitis—Epirubicin—urinary bladder cancer	0.000268	0.000422	CcSEcCtD
Cevimeline—Feeling abnormal—Etoposide—urinary bladder cancer	0.000268	0.000422	CcSEcCtD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—urinary bladder cancer	0.000268	0.00172	CbGpPWpGaD
Cevimeline—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000267	0.000421	CcSEcCtD
Cevimeline—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000266	0.00042	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—urinary bladder cancer	0.000266	0.000419	CcSEcCtD
Cevimeline—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000266	0.000418	CcSEcCtD
Cevimeline—Pruritus—Fluorouracil—urinary bladder cancer	0.000265	0.000417	CcSEcCtD
Cevimeline—FMO1—Metabolism—NQO1—urinary bladder cancer	0.000265	0.0017	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000264	0.0017	CbGpPWpGaD
Cevimeline—Visual impairment—Methotrexate—urinary bladder cancer	0.000264	0.000416	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000261	0.00168	CbGpPWpGaD
Cevimeline—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000261	0.000412	CcSEcCtD
Cevimeline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00026	0.00041	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000259	0.000408	CcSEcCtD
Cevimeline—Urticaria—Etoposide—urinary bladder cancer	0.000258	0.000407	CcSEcCtD
Cevimeline—Haemoglobin—Epirubicin—urinary bladder cancer	0.000258	0.000406	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—urinary bladder cancer	0.000258	0.000406	CcSEcCtD
Cevimeline—Rhinitis—Epirubicin—urinary bladder cancer	0.000257	0.000405	CcSEcCtD
Cevimeline—Abdominal pain—Etoposide—urinary bladder cancer	0.000257	0.000405	CcSEcCtD
Cevimeline—Body temperature increased—Etoposide—urinary bladder cancer	0.000257	0.000405	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000257	0.000405	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000257	0.000405	CcSEcCtD
Cevimeline—Haemorrhage—Epirubicin—urinary bladder cancer	0.000256	0.000404	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—urinary bladder cancer	0.000256	0.000403	CcSEcCtD
Cevimeline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000256	0.000403	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—urinary bladder cancer	0.000255	0.000402	CcSEcCtD
Cevimeline—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000255	0.000402	CcSEcCtD
Cevimeline—Asthenia—Cisplatin—urinary bladder cancer	0.000254	0.000401	CcSEcCtD
Cevimeline—Pharyngitis—Epirubicin—urinary bladder cancer	0.000254	0.000401	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000254	0.0004	CcSEcCtD
Cevimeline—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000252	0.000398	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—urinary bladder cancer	0.000252	0.000397	CcSEcCtD
Cevimeline—Urethral disorder—Epirubicin—urinary bladder cancer	0.000251	0.000396	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—urinary bladder cancer	0.000249	0.000393	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—urinary bladder cancer	0.000248	0.000391	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—urinary bladder cancer	0.000248	0.00039	CcSEcCtD
Cevimeline—Dizziness—Fluorouracil—urinary bladder cancer	0.000247	0.00039	CcSEcCtD
Cevimeline—Visual impairment—Epirubicin—urinary bladder cancer	0.000247	0.000389	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000247	0.000388	CcSEcCtD
Cevimeline—Chills—Methotrexate—urinary bladder cancer	0.000246	0.000387	CcSEcCtD
Cevimeline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000243	0.000382	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—urinary bladder cancer	0.000242	0.000381	CcSEcCtD
Cevimeline—Vomiting—Gemcitabine—urinary bladder cancer	0.000242	0.000381	CcSEcCtD
Cevimeline—Rash—Gemcitabine—urinary bladder cancer	0.00024	0.000378	CcSEcCtD
Cevimeline—Dermatitis—Gemcitabine—urinary bladder cancer	0.00024	0.000378	CcSEcCtD
Cevimeline—Eye disorder—Epirubicin—urinary bladder cancer	0.00024	0.000377	CcSEcCtD
Cevimeline—Hypersensitivity—Etoposide—urinary bladder cancer	0.000239	0.000377	CcSEcCtD
Cevimeline—Tinnitus—Epirubicin—urinary bladder cancer	0.000239	0.000376	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—urinary bladder cancer	0.000238	0.000376	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000238	0.000376	CcSEcCtD
Cevimeline—Headache—Gemcitabine—urinary bladder cancer	0.000238	0.000375	CcSEcCtD
Cevimeline—Flushing—Epirubicin—urinary bladder cancer	0.000238	0.000375	CcSEcCtD
Cevimeline—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000238	0.000375	CcSEcCtD
Cevimeline—Vomiting—Fluorouracil—urinary bladder cancer	0.000238	0.000375	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—urinary bladder cancer	0.000238	0.000375	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000237	0.000374	CcSEcCtD
Cevimeline—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000236	0.000372	CcSEcCtD
Cevimeline—Rash—Fluorouracil—urinary bladder cancer	0.000236	0.000372	CcSEcCtD
Cevimeline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000236	0.000371	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000235	0.000371	CcSEcCtD
Cevimeline—Headache—Fluorouracil—urinary bladder cancer	0.000234	0.000369	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—FAS—urinary bladder cancer	0.000234	0.00151	CbGpPWpGaD
Cevimeline—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000234	0.000368	CcSEcCtD
Cevimeline—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000234	0.0015	CbGpPWpGaD
Cevimeline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000233	0.000368	CcSEcCtD
Cevimeline—Asthenia—Etoposide—urinary bladder cancer	0.000233	0.000367	CcSEcCtD
Cevimeline—Angiopathy—Epirubicin—urinary bladder cancer	0.000233	0.000366	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000366	CcSEcCtD
Cevimeline—Back pain—Methotrexate—urinary bladder cancer	0.000231	0.000363	CcSEcCtD
Cevimeline—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00023	0.00148	CbGpPWpGaD
Cevimeline—Chills—Epirubicin—urinary bladder cancer	0.00023	0.000362	CcSEcCtD
Cevimeline—Pruritus—Etoposide—urinary bladder cancer	0.00023	0.000362	CcSEcCtD
Cevimeline—Arrhythmia—Epirubicin—urinary bladder cancer	0.000229	0.000361	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—urinary bladder cancer	0.000229	0.00036	CcSEcCtD
Cevimeline—Alopecia—Epirubicin—urinary bladder cancer	0.000226	0.000357	CcSEcCtD
Cevimeline—Nausea—Gemcitabine—urinary bladder cancer	0.000226	0.000356	CcSEcCtD
Cevimeline—Vomiting—Cisplatin—urinary bladder cancer	0.000225	0.000355	CcSEcCtD
Cevimeline—Rash—Cisplatin—urinary bladder cancer	0.000224	0.000352	CcSEcCtD
Cevimeline—Dermatitis—Cisplatin—urinary bladder cancer	0.000223	0.000352	CcSEcCtD
Cevimeline—Malnutrition—Epirubicin—urinary bladder cancer	0.000223	0.000352	CcSEcCtD
Cevimeline—Diarrhoea—Etoposide—urinary bladder cancer	0.000222	0.00035	CcSEcCtD
Cevimeline—Nausea—Fluorouracil—urinary bladder cancer	0.000222	0.00035	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—urinary bladder cancer	0.000222	0.000349	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000221	0.000349	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—urinary bladder cancer	0.000221	0.000348	CcSEcCtD
Cevimeline—FMO1—Metabolism—GSTP1—urinary bladder cancer	0.000221	0.00142	CbGpPWpGaD
Cevimeline—Anaemia—Methotrexate—urinary bladder cancer	0.00022	0.000347	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—urinary bladder cancer	0.00022	0.000347	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00022	0.000347	CcSEcCtD
Cevimeline—Flatulence—Epirubicin—urinary bladder cancer	0.00022	0.000346	CcSEcCtD
Cevimeline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000219	0.000344	CcSEcCtD
Cevimeline—Back pain—Epirubicin—urinary bladder cancer	0.000216	0.00034	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—urinary bladder cancer	0.000215	0.000339	CcSEcCtD
Cevimeline—Malaise—Methotrexate—urinary bladder cancer	0.000215	0.000339	CcSEcCtD
Cevimeline—Dizziness—Etoposide—urinary bladder cancer	0.000215	0.000338	CcSEcCtD
Cevimeline—Muscle spasms—Epirubicin—urinary bladder cancer	0.000215	0.000338	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—urinary bladder cancer	0.000214	0.000337	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—urinary bladder cancer	0.000213	0.000336	CcSEcCtD
Cevimeline—Chills—Doxorubicin—urinary bladder cancer	0.000213	0.000335	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000212	0.000334	CcSEcCtD
Cevimeline—Nausea—Cisplatin—urinary bladder cancer	0.000211	0.000332	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—urinary bladder cancer	0.00021	0.00033	CcSEcCtD
Cevimeline—Cough—Methotrexate—urinary bladder cancer	0.000208	0.000328	CcSEcCtD
Cevimeline—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000207	0.000326	CcSEcCtD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—RHOA—urinary bladder cancer	0.000207	0.00133	CbGpPWpGaD
Cevimeline—Convulsion—Methotrexate—urinary bladder cancer	0.000207	0.000325	CcSEcCtD
Cevimeline—Vomiting—Etoposide—urinary bladder cancer	0.000207	0.000325	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—urinary bladder cancer	0.000206	0.000325	CcSEcCtD
Cevimeline—Anaemia—Epirubicin—urinary bladder cancer	0.000206	0.000325	CcSEcCtD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—RHOA—urinary bladder cancer	0.000206	0.00133	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000206	0.00132	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—TYMS—urinary bladder cancer	0.000205	0.00132	CbGpPWpGaD
Cevimeline—Agitation—Epirubicin—urinary bladder cancer	0.000205	0.000323	CcSEcCtD
Cevimeline—Rash—Etoposide—urinary bladder cancer	0.000205	0.000323	CcSEcCtD
Cevimeline—Dermatitis—Etoposide—urinary bladder cancer	0.000205	0.000322	CcSEcCtD
Cevimeline—Headache—Etoposide—urinary bladder cancer	0.000204	0.000321	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—urinary bladder cancer	0.000203	0.00032	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—urinary bladder cancer	0.000203	0.00032	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—urinary bladder cancer	0.000203	0.00032	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—urinary bladder cancer	0.000203	0.00032	CcSEcCtD
Cevimeline—FMO1—Metabolism—NCOR1—urinary bladder cancer	0.000203	0.0013	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GSTM1—urinary bladder cancer	0.000203	0.0013	CbGpPWpGaD
Cevimeline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000202	0.000318	CcSEcCtD
Cevimeline—Malaise—Epirubicin—urinary bladder cancer	0.000201	0.000317	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—urinary bladder cancer	0.000201	0.000316	CcSEcCtD
Cevimeline—Vertigo—Epirubicin—urinary bladder cancer	0.0002	0.000316	CcSEcCtD
Cevimeline—Syncope—Epirubicin—urinary bladder cancer	0.0002	0.000315	CcSEcCtD
Cevimeline—Leukopenia—Epirubicin—urinary bladder cancer	0.0002	0.000315	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—urinary bladder cancer	0.0002	0.000315	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000198	0.000313	CcSEcCtD
Cevimeline—Palpitations—Epirubicin—urinary bladder cancer	0.000197	0.000311	CcSEcCtD
Cevimeline—CHRM3—Metabolism—GSTZ1—urinary bladder cancer	0.000197	0.00126	CbGpPWpGaD
Cevimeline—Confusional state—Methotrexate—urinary bladder cancer	0.000196	0.000309	CcSEcCtD
Cevimeline—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000196	0.000309	CcSEcCtD
Cevimeline—Cough—Epirubicin—urinary bladder cancer	0.000195	0.000307	CcSEcCtD
Cevimeline—FMO1—Metabolism—GPX1—urinary bladder cancer	0.000194	0.00125	CbGpPWpGaD
Cevimeline—Convulsion—Epirubicin—urinary bladder cancer	0.000193	0.000305	CcSEcCtD
Cevimeline—Infection—Methotrexate—urinary bladder cancer	0.000193	0.000305	CcSEcCtD
Cevimeline—Nausea—Etoposide—urinary bladder cancer	0.000193	0.000304	CcSEcCtD
Cevimeline—Hypertension—Epirubicin—urinary bladder cancer	0.000193	0.000303	CcSEcCtD
Cevimeline—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000192	0.00123	CbGpPWpGaD
Cevimeline—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000192	0.000302	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000191	0.000301	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—urinary bladder cancer	0.000191	0.000301	CcSEcCtD
Cevimeline—FMO1—Metabolism—ERCC2—urinary bladder cancer	0.000191	0.00123	CbGpPWpGaD
Cevimeline—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000191	0.0003	CcSEcCtD
Cevimeline—Arthralgia—Epirubicin—urinary bladder cancer	0.00019	0.000299	CcSEcCtD
Cevimeline—Myalgia—Epirubicin—urinary bladder cancer	0.00019	0.000299	CcSEcCtD
Cevimeline—Chest pain—Epirubicin—urinary bladder cancer	0.00019	0.000299	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—urinary bladder cancer	0.00019	0.000299	CcSEcCtD
Cevimeline—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000189	0.00122	CbGpPWpGaD
Cevimeline—Anxiety—Epirubicin—urinary bladder cancer	0.000189	0.000298	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—urinary bladder cancer	0.000189	0.000298	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000188	0.000296	CcSEcCtD
Cevimeline—Discomfort—Epirubicin—urinary bladder cancer	0.000188	0.000296	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000187	0.0012	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000187	0.0012	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTO2—urinary bladder cancer	0.000186	0.0012	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NAT1—urinary bladder cancer	0.000186	0.0012	CbGpPWpGaD
Cevimeline—Malaise—Doxorubicin—urinary bladder cancer	0.000186	0.000293	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—urinary bladder cancer	0.000185	0.000292	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—urinary bladder cancer	0.000185	0.000292	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—urinary bladder cancer	0.000185	0.000292	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—urinary bladder cancer	0.000185	0.000291	CcSEcCtD
Cevimeline—Confusional state—Epirubicin—urinary bladder cancer	0.000184	0.000289	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—urinary bladder cancer	0.000182	0.000287	CcSEcCtD
Cevimeline—Oedema—Epirubicin—urinary bladder cancer	0.000182	0.000287	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—urinary bladder cancer	0.000182	0.000286	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000181	0.000286	CcSEcCtD
Cevimeline—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000181	0.00116	CbGpPWpGaD
Cevimeline—Infection—Epirubicin—urinary bladder cancer	0.000181	0.000285	CcSEcCtD
Cevimeline—Cough—Doxorubicin—urinary bladder cancer	0.00018	0.000284	CcSEcCtD
Cevimeline—FMO1—Metabolism—MTHFR—urinary bladder cancer	0.000179	0.00115	CbGpPWpGaD
Cevimeline—Shock—Epirubicin—urinary bladder cancer	0.000179	0.000282	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—urinary bladder cancer	0.000179	0.000282	CcSEcCtD
Cevimeline—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000179	0.000281	CcSEcCtD
Cevimeline—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000178	0.000281	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—urinary bladder cancer	0.000178	0.000281	CcSEcCtD
Cevimeline—Tachycardia—Epirubicin—urinary bladder cancer	0.000178	0.00028	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000177	0.000279	CcSEcCtD
Cevimeline—Skin disorder—Epirubicin—urinary bladder cancer	0.000177	0.000279	CcSEcCtD
Cevimeline—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000176	0.00113	CbGpPWpGaD
Cevimeline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000176	0.000277	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—urinary bladder cancer	0.000176	0.000277	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—urinary bladder cancer	0.000176	0.000277	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—urinary bladder cancer	0.000176	0.000277	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—urinary bladder cancer	0.000176	0.000277	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—urinary bladder cancer	0.000175	0.000276	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—urinary bladder cancer	0.000175	0.000275	CcSEcCtD
Cevimeline—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000174	0.00112	CbGpPWpGaD
Cevimeline—Discomfort—Doxorubicin—urinary bladder cancer	0.000174	0.000274	CcSEcCtD
Cevimeline—Anorexia—Epirubicin—urinary bladder cancer	0.000174	0.000273	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—urinary bladder cancer	0.000173	0.000273	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—urinary bladder cancer	0.000173	0.000273	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—urinary bladder cancer	0.000171	0.00027	CcSEcCtD
Cevimeline—CHRM3—Metabolism—UGT2B7—urinary bladder cancer	0.000171	0.0011	CbGpPWpGaD
Cevimeline—Hypotension—Epirubicin—urinary bladder cancer	0.00017	0.000268	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—urinary bladder cancer	0.00017	0.000268	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—urinary bladder cancer	0.000169	0.000266	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—urinary bladder cancer	0.000168	0.000265	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—urinary bladder cancer	0.000168	0.000264	CcSEcCtD
Cevimeline—Infection—Doxorubicin—urinary bladder cancer	0.000167	0.000264	CcSEcCtD
Cevimeline—Pain—Methotrexate—urinary bladder cancer	0.000166	0.000262	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000166	0.000261	CcSEcCtD
Cevimeline—Shock—Doxorubicin—urinary bladder cancer	0.000166	0.000261	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000165	0.00026	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000165	0.00026	CcSEcCtD
Cevimeline—Insomnia—Epirubicin—urinary bladder cancer	0.000165	0.000259	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—urinary bladder cancer	0.000164	0.000259	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—urinary bladder cancer	0.000164	0.000258	CcSEcCtD
Cevimeline—Paraesthesia—Epirubicin—urinary bladder cancer	0.000164	0.000258	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000163	0.000257	CcSEcCtD
Cevimeline—Dyspnoea—Epirubicin—urinary bladder cancer	0.000162	0.000256	CcSEcCtD
Cevimeline—Somnolence—Epirubicin—urinary bladder cancer	0.000162	0.000255	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—urinary bladder cancer	0.000161	0.000253	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00016	0.000253	CcSEcCtD
Cevimeline—Dyspepsia—Epirubicin—urinary bladder cancer	0.00016	0.000253	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000159	0.000251	CcSEcCtD
Cevimeline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000158	0.000249	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—urinary bladder cancer	0.000157	0.000248	CcSEcCtD
Cevimeline—Fatigue—Epirubicin—urinary bladder cancer	0.000157	0.000247	CcSEcCtD
Cevimeline—Constipation—Epirubicin—urinary bladder cancer	0.000156	0.000245	CcSEcCtD
Cevimeline—Pain—Epirubicin—urinary bladder cancer	0.000156	0.000245	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—urinary bladder cancer	0.000155	0.000244	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000154	0.000242	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000154	0.000242	CcSEcCtD
Cevimeline—CHRM3—Metabolism—CYP4B1—urinary bladder cancer	0.000154	0.000987	CbGpPWpGaD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000154	0.000242	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—urinary bladder cancer	0.000152	0.00024	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000151	0.000238	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00015	0.000237	CcSEcCtD
Cevimeline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00015	0.000236	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—urinary bladder cancer	0.00015	0.000236	CcSEcCtD
Cevimeline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000149	0.000235	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000148	0.000234	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000146	0.000231	CcSEcCtD
Cevimeline—FMO1—Metabolism—PPARG—urinary bladder cancer	0.000145	0.000934	CbGpPWpGaD
Cevimeline—Fatigue—Doxorubicin—urinary bladder cancer	0.000145	0.000229	CcSEcCtD
Cevimeline—CHRM3—Metabolism—SLC19A1—urinary bladder cancer	0.000145	0.000932	CbGpPWpGaD
Cevimeline—Urticaria—Epirubicin—urinary bladder cancer	0.000145	0.000228	CcSEcCtD
Cevimeline—Pain—Doxorubicin—urinary bladder cancer	0.000144	0.000227	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—urinary bladder cancer	0.000144	0.000227	CcSEcCtD
Cevimeline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000144	0.000227	CcSEcCtD
Cevimeline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000144	0.000227	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000143	0.000226	CcSEcCtD
Cevimeline—CHRM3—Metabolism—PRSS3—urinary bladder cancer	0.000141	0.000908	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CREBBP—urinary bladder cancer	0.00014	0.000898	CbGpPWpGaD
Cevimeline—Asthenia—Methotrexate—urinary bladder cancer	0.00014	0.00022	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000139	0.000219	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000138	0.000217	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—urinary bladder cancer	0.000138	0.000217	CcSEcCtD
Cevimeline—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000134	0.000211	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—urinary bladder cancer	0.000134	0.000211	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000133	0.00021	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000133	0.00021	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—urinary bladder cancer	0.000133	0.00021	CcSEcCtD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000133	0.000853	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.000132	0.00085	CbGpPWpGaD
Cevimeline—Asthenia—Epirubicin—urinary bladder cancer	0.000131	0.000206	CcSEcCtD
Cevimeline—Pruritus—Epirubicin—urinary bladder cancer	0.000129	0.000203	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—urinary bladder cancer	0.000129	0.000203	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000128	0.000826	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000126	0.000807	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	0.000125	0.000806	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	0.000125	0.000803	CbGpPWpGaD
Cevimeline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000125	0.000196	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000124	0.000196	CcSEcCtD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000124	0.000796	CbGpPWpGaD
Cevimeline—Vomiting—Methotrexate—urinary bladder cancer	0.000124	0.000195	CcSEcCtD
Cevimeline—Rash—Methotrexate—urinary bladder cancer	0.000123	0.000193	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—urinary bladder cancer	0.000123	0.000193	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—EP300—urinary bladder cancer	0.000123	0.000788	CbGpPWpGaD
Cevimeline—Headache—Methotrexate—urinary bladder cancer	0.000122	0.000192	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—urinary bladder cancer	0.000121	0.00019	CcSEcCtD
Cevimeline—Dizziness—Epirubicin—urinary bladder cancer	0.00012	0.00019	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—urinary bladder cancer	0.000119	0.000188	CcSEcCtD
Cevimeline—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000118	0.000756	CbGpPWpGaD
Cevimeline—Vomiting—Epirubicin—urinary bladder cancer	0.000116	0.000182	CcSEcCtD
Cevimeline—Nausea—Methotrexate—urinary bladder cancer	0.000116	0.000182	CcSEcCtD
Cevimeline—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000115	0.000741	CbGpPWpGaD
Cevimeline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000115	0.000182	CcSEcCtD
Cevimeline—Rash—Epirubicin—urinary bladder cancer	0.000115	0.000181	CcSEcCtD
Cevimeline—Dermatitis—Epirubicin—urinary bladder cancer	0.000115	0.000181	CcSEcCtD
Cevimeline—FMO1—Metabolism—PTGS2—urinary bladder cancer	0.000114	0.000735	CbGpPWpGaD
Cevimeline—Headache—Epirubicin—urinary bladder cancer	0.000114	0.00018	CcSEcCtD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000114	0.000731	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000113	0.000727	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TYMP—urinary bladder cancer	0.000113	0.000726	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HDAC4—urinary bladder cancer	0.000113	0.000725	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000111	0.000717	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000111	0.000717	CbGpPWpGaD
Cevimeline—Dizziness—Doxorubicin—urinary bladder cancer	0.000111	0.000176	CcSEcCtD
Cevimeline—Nausea—Epirubicin—urinary bladder cancer	0.000108	0.00017	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—urinary bladder cancer	0.000107	0.000169	CcSEcCtD
Cevimeline—Rash—Doxorubicin—urinary bladder cancer	0.000106	0.000167	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000106	0.000167	CcSEcCtD
Cevimeline—Headache—Doxorubicin—urinary bladder cancer	0.000106	0.000166	CcSEcCtD
Cevimeline—CHRM3—Metabolism—NAT2—urinary bladder cancer	0.000102	0.000657	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000102	0.000655	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.0001	0.000644	CbGpPWpGaD
Cevimeline—Nausea—Doxorubicin—urinary bladder cancer	0.0001	0.000158	CcSEcCtD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	9.99e-05	0.000642	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTEN—urinary bladder cancer	9.97e-05	0.000641	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	9.89e-05	0.000636	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	9.86e-05	0.000634	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—EP300—urinary bladder cancer	9.51e-05	0.000611	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GLI1—urinary bladder cancer	9.47e-05	0.000609	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GLI1—urinary bladder cancer	9.44e-05	0.000607	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	9.35e-05	0.000601	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	9.32e-05	0.000599	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	9.18e-05	0.00059	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—RRM2—urinary bladder cancer	8.82e-05	0.000567	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—urinary bladder cancer	8.77e-05	0.000564	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	8.67e-05	0.000557	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	8.45e-05	0.000543	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HPGDS—urinary bladder cancer	8.17e-05	0.000525	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ENO2—urinary bladder cancer	8.17e-05	0.000525	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	7.94e-05	0.000511	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTT1—urinary bladder cancer	7.92e-05	0.000509	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	7.92e-05	0.000509	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.69e-05	0.000494	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	7.63e-05	0.000491	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CXCL8—urinary bladder cancer	7.61e-05	0.000489	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.29e-05	0.000469	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.29e-05	0.000469	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMP—urinary bladder cancer	6.75e-05	0.000434	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.67e-05	0.000429	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NQO1—urinary bladder cancer	6.58e-05	0.000423	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RBX1—urinary bladder cancer	6.49e-05	0.000417	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RBX1—urinary bladder cancer	6.47e-05	0.000416	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NAT2—urinary bladder cancer	6.11e-05	0.000393	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TSC1—urinary bladder cancer	6.11e-05	0.000393	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TSC1—urinary bladder cancer	6.09e-05	0.000391	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6e-05	0.000386	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JAG1—urinary bladder cancer	5.81e-05	0.000374	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JAG1—urinary bladder cancer	5.79e-05	0.000372	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.67e-05	0.000364	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.52e-05	0.000355	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTP1—urinary bladder cancer	5.49e-05	0.000353	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.27e-05	0.000339	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TYMS—urinary bladder cancer	5.1e-05	0.000328	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NCOR1—urinary bladder cancer	5.05e-05	0.000324	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTM1—urinary bladder cancer	5.05e-05	0.000324	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	4.91e-05	0.000316	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—RHOA—urinary bladder cancer	4.9e-05	0.000315	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.88e-05	0.000314	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.88e-05	0.000314	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GPX1—urinary bladder cancer	4.83e-05	0.000311	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ERCC2—urinary bladder cancer	4.74e-05	0.000305	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.74e-05	0.000304	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	4.71e-05	0.000303	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—S100B—urinary bladder cancer	4.69e-05	0.000302	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	4.46e-05	0.000287	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MTHFR—urinary bladder cancer	4.46e-05	0.000287	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RHOA—urinary bladder cancer	4.45e-05	0.000286	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.42e-05	0.000284	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.31e-05	0.000277	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.3e-05	0.000276	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	4.23e-05	0.000272	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NCOR1—urinary bladder cancer	4.22e-05	0.000271	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	4.12e-05	0.000265	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—urinary bladder cancer	4.11e-05	0.000264	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.99e-05	0.000257	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.94e-05	0.000253	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.92e-05	0.000252	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL8—urinary bladder cancer	3.9e-05	0.000251	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	3.74e-05	0.000241	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—urinary bladder cancer	3.73e-05	0.00024	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	3.73e-05	0.00024	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TERT—urinary bladder cancer	3.72e-05	0.000239	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARG—urinary bladder cancer	3.62e-05	0.000232	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CREBBP—urinary bladder cancer	3.47e-05	0.000223	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.45e-05	0.000222	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	3.42e-05	0.00022	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGFR3—urinary bladder cancer	3.41e-05	0.000219	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	3.32e-05	0.000214	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ESR1—urinary bladder cancer	3.31e-05	0.000213	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.28e-05	0.000211	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.19e-05	0.000205	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.19e-05	0.000205	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.1e-05	0.000199	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.05e-05	0.000196	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.02e-05	0.000194	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.02e-05	0.000194	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	2.91e-05	0.000187	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	2.9e-05	0.000187	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.89e-05	0.000186	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	2.88e-05	0.000185	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	2.87e-05	0.000184	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	2.86e-05	0.000184	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	2.85e-05	0.000183	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—urinary bladder cancer	2.84e-05	0.000183	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.84e-05	0.000182	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	2.7e-05	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	2.7e-05	0.000173	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.67e-05	0.000171	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	2.64e-05	0.000169	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	2.63e-05	0.000169	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.57e-05	0.000165	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTEN—urinary bladder cancer	2.48e-05	0.000159	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	2.44e-05	0.000157	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	2.43e-05	0.000156	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—EP300—urinary bladder cancer	2.37e-05	0.000152	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	2.31e-05	0.000149	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	2.31e-05	0.000148	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	2.3e-05	0.000148	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	2.29e-05	0.000147	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	2.21e-05	0.000142	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	2.2e-05	0.000142	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.16e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	2.16e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	2.15e-05	0.000138	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.15e-05	0.000138	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	2.09e-05	0.000135	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	2.09e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.09e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	2.08e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	2.08e-05	0.000134	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.08e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	2.07e-05	0.000133	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2e-05	0.000128	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.98e-05	0.000128	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	1.98e-05	0.000127	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	0.000127	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.93e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	1.92e-05	0.000124	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.89e-05	0.000121	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.85e-05	0.000119	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	0.000112	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.73e-05	0.000111	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	1.72e-05	0.000111	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.7e-05	0.000109	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.69e-05	0.000109	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	1.69e-05	0.000108	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.6e-05	0.000103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	1.59e-05	0.000102	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.48e-05	9.54e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	1.42e-05	9.13e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	1.42e-05	9.1e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.41e-05	9.09e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.41e-05	9.09e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	1.36e-05	8.73e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.36e-05	8.73e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	1.35e-05	8.7e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	7.15e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTEN—urinary bladder cancer	9.7e-06	6.23e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.25e-06	5.95e-05	CbGpPWpGaD
